Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 10/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30137005 | 1.00 | SLC5A2 (0.42) | SLC5A2GSK3BRAB9AKDM1AMAOA | |
| SCHEMBL14128414 | 0.85 | SLC5A2 (0.53) | SLC5A2MAOBSLC5A1LMNAMAPT | |
| SCHEMBL19019454 | 0.81 | SLC5A2 (0.44) | SLC5A2GSK3BRAB9AKDM1AMAOA | |
| SCHEMBL20139367 | 0.80 | SLC5A2 (0.48) | SLC5A2SLC5A1 | |
| SCHEMBL1670103 | 0.78 | SLC5A2 (0.43) | SLC5A2SLC5A1LMNAMAPTHTT | |
| SCHEMBL20139399 | 0.78 | SLC5A2 (0.42) | SLC5A2POLBSLC5A1 | |
| SCHEMBL19019416 | 0.78 | SLC5A2 (0.48) | SLC5A2GSK3BSLC5A1 | |
| SCHEMBL155111 | 0.75 | MAPT (0.53) | RAB9AMAOBNPC1LMNAMAPT | |
| SCHEMBL29584634 | 0.75 | MAPT (0.53) | RAB9AMAOBNPC1LMNAMAPT | |
| SCHEMBL28524657 | 0.74 | SLC5A2 (0.51) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113135966-B | Bicyclic derivatives of heterocyclic glucoside and preparation method and application thereof | 华润双鹤药业股份有限公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-113135966-A | Bicyclic derivatives of heterocyclic glucoside and preparation method and application thereof | 华润双鹤药业股份有限公司 | 2021-07-20 | — | — | CN | disclosed |
| EP-2604612-B1 | C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION RPOCESS AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARM CO LTD (CN) | 2016-04-20 | — | — | EP | disclosed |
| EP-2604612-B1 | C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION RPOCESS AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARM CO LTD (CN) | 2016-04-20 | — | — | EP | disclosed |
| US-8609622-B2 | C-aryl glucoside derivatives, preparation process and pharmaceutical use thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2013-12-17 | — | — | US | disclosed |
| EP-2604612-A1 | C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION RPOCESS AND PHARMACEUTICAL USE THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2013-06-19 | — | — | EP | disclosed |
| US-20130130997-A1 | C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2013-05-23 | — | — | US | disclosed |
| US-20130130997-A1 | C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2013-05-23 | — | — | US | disclosed |
| US-20130130997-A1 | C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2013-05-23 | — | — | US | disclosed |
| CN-102372722-A | C-aryl glucoside derivative, preparation method thereof and application of C-aryl glucoside derivative in medicine | JIANGSU HENGRUI MEDICINE CO | 2012-03-14 | — | — | CN | disclosed |
| WO-2012019496-A1 | C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION RPOCESS AND PHARMACEUTICAL USE THEREOF | 上海恒瑞医药有限公司 (CN) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130130997-A1 | C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | SLC5A1, SLC5A2, UGGT1 | SLC5A2 2/4885GSK3B 425/4885RAB9A 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.